Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability
Joint Authors
Køstner, Anne Helene
Sorensen, Morten
Olesen, René Krøjgaard
Ladekarl, M.
Lassen, Ulrik
Gronbaek, Henning
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-01-28
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Medicine
Information Technology and Computer Science
Abstract EN
Background.
Advanced HCC is a clinical challenge with limited treatment options.
The multikinase inhibitor sorafenib is the first and only agent showing a survival benefit in these patients.
In this study we evaluate the efficacy and tolerability of sorafenib in an unselected patient population.
Furthermore we explore the role of alpha-fetoprotein (αFP) as a potential biomarker for treatment efficacy and correlation to survival.
Methods.
Seventy-six patients with advanced HCC, not eligible for locoregional therapy, treated with sorafenib between 2007 and 2009 were included.
Followup was until 2011.
Results.
Patients in PS 0-1 had a median overall survival (mOS) of 6.2 months, compared to 1.8 months in patients with poorer PS (P=0.005).
Child-Pugh A patients had a mOS of 6.6 months versus 3.6 months among patients in Child-Pugh B or C (P=0.0001).
Serum αFP ≥ 200 at baseline was prognostic for a shorter survival.
All patients with radiologically verified tumor response and baseline αFP ≥ 200 experienced a significant decline in αFP within the first four weeks of treatment.
Conclusion.
The survival of patients with advanced HCC treated with sorafenib is dependent on performance status and liver function.
Treatment of patients with compromised liver function and poor performance status cannot be recommended.
The correlation between αFP and objective tumor response warrants further investigation.
American Psychological Association (APA)
Køstner, Anne Helene& Sorensen, Morten& Olesen, René Krøjgaard& Gronbaek, Henning& Lassen, Ulrik& Ladekarl, M.. 2013. Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability. The Scientific World Journal،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-1033453
Modern Language Association (MLA)
Køstner, Anne Helene…[et al.]. Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability. The Scientific World Journal No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-1033453
American Medical Association (AMA)
Køstner, Anne Helene& Sorensen, Morten& Olesen, René Krøjgaard& Gronbaek, Henning& Lassen, Ulrik& Ladekarl, M.. Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability. The Scientific World Journal. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-1033453
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1033453